Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics / Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months of it, or refractory or relapsing after first line and ineligible for hematopoietic stem cell transplantation due to age or comorbidities.
LAMPGEN ANALYSIS
Why it matters
The action reaches early-relapsing disease and a separate group unable to proceed to transplant.
What research teams should watch
Record the relapse interval and the rationale for transplant ineligibility. Coordinate CAR T referral and collection.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
CAR T-cell studies in relapsed or refractory DLBCLPRIMARY RECORDS